349 Results for "

driven

" in MedChemExpress (MCE) Product Catalog:
Products (349)

349 Results for "driven" in MCE Product Catalog:

71
71 Publications Verification
Cat. No.: HY-13323
CAS No.: 1138549-36-6
Purity:  99.49%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-18300
CAS No.: 1206161-97-8
Synonyms: GLPG0634
Target:  

JAK HIV

Research Areas:  

Cancer

Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-18300A
CAS No.: 1802998-75-9
Synonyms: GLPG0634 maleate
Target:  

JAK HIV

Research Areas:  

Inflammation/Immunology

Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values ​​of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-112929
CAS No.: 1809427-19-7
Purity:  99.83%
Target:  

Phosphatase

Research Areas:  

Cancer

DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19719
CAS No.: 1313881-70-7
Synonyms: ARQ-092
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19719A
CAS No.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257
CAS No.: 1957203-01-8
Purity:  98.79%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257B
CAS No.: 2748220-93-9
Purity:  99.74%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-19744
CAS No.: 2437475-16-4
Target:  

MyD88

Research Areas:  

Inflammation/Immunology

T6167923 is a selective inhibitor of MyD88-dependent signaling pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation. T6167923 inhibits NF-κB driven Staphylococcus enterotoxin AP (SEAP) activity, and improves anti-inflammatory activity with IC50s of 2.7 μM, 2.9 μM, 2.66 μM and 2.66 μM for IFN-γ, IL-1β, IL-6 and TNF-α, respectively .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-145010
CAS No.: 2249435-90-1
Purity:  99.73%
Target:  

STING

Research Areas:  

Inflammation/Immunology

SN-011 is a potent and selective mouse and human STING inhibitor, with an IC50 of 76 nM for STING signaling. SN-011 competes with cyclic dinucleotide (CDN) for the binding pocket of the STING dimer, blocking CDN binding and STING activation. SN-011 can be used for the research of STING-driven autoimmune and inflammatory disease .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-100237
CAS No.: 222716-34-9
Purity:  99.07%
Research Areas:  

Cancer

SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-162288
CAS No.: 3036029-72-5
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

FAZ-3532 is a G3BP inhibitor (Kd = 0.54 μM) which binds to the NTF2L nsP3 binding pocket in G3BP1. FAZ-3532 disrupts the co-condensation of RNA, G3BP1, and caprin 1. FAZ-3532 inhibits G3BP-driven stress granule formation. FAZ-3532 can be studied as a powerful tool to probe the biology of stress granules and a promising interventions designed to modulate stress granule formation .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-124500
CAS No.: 1834571-82-2
Purity:  99.93%
Target:  

STAT Apoptosis

Research Areas:  

Cancer

AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-136579
CAS No.: 2055597-12-9
Purity:  99.70%
Synonyms: ERK-IN-3
Target:  

ERK

Research Areas:  

Cancer

ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK. ASN007 inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 exhibits significant anti proliferative activity against various tumor cells. ASN007 can be used for the research of cancers driven by RAS mutations .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-136579A
CAS No.: 2055597-39-0
Purity:  99.72%
Synonyms: ERK-IN-3 benzenesulfonate
Target:  

ERK

Research Areas:  

Cancer

ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of ERK. ASN007 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 benzenesulfonate exhibits significant anti proliferative activity against various tumor cells. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-136270
CAS No.: 1613191-99-3
Purity:  99.77%
Synonyms: VX-803; M4344; ATR inhibitor 2
Target:  

ATM/ATR

Research Areas:  

Cancer

Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-121802
CAS No.: 2222768-84-3
Purity:  98.18%
Target:  

Hedgehog

Research Areas:  

Cancer

Dynarrestin is a aminothiazole inhibitor of cytoplasmic dyneins 1 and 2. Dynarrestin rapidly and reversibly inhibits dynein 1-driven microtubule gliding in vitro plus a range of dynein 1- and 2-dependent processes in cells without affecting ATP hydrolysis and interfering with ciliogenesis. Dynarrestin suppresses hedgehog (Hh)-dependent proliferation of neuronal precursors and tumor cells .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-19706
CAS No.: 1629268-00-3
Target:  

Ras Apoptosis

Research Areas:  

Cancer

ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor with an IC50 of 2.5 μM. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-112296
CAS No.: 2407433-00-3
Purity:  99.64%
Target:  

CDK Apoptosis DYRK

Research Areas:  

Cancer

T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-139361
CAS No.: 2451481-08-4
Purity:  99.82%
Synonyms: PIN1-3
Target:  

PIN1

Research Areas:  

Cancer

Sulfopin (PIN1-3) is a highly selective covalent inhibitor of Pin1 with an apparent Ki of 17 nM. Sulfopin blocks Myc-driven tumors in vivo. The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate tumor suppressors .
loading...
    loading...